No Data
No Data
Huaren Pharmaceutical (300110.SZ): Its subsidiary Anhui Hengxing Pharmaceutical has obtained a drug registration certificate for its Ketamine Hydrochloride Injection.
On August 5, Gelunhui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui Hengxing Pharmaceutical") has received the "Drug Registration Certificate" for Ketococonazole Injection approved and issued by the National Medical Products Administration. Ketococonazole Injection is suitable for peripheral arterial disease (intermittent claudication or rest pain) and inner ear circulation disorder, and is a category B medical insurance product in China.
Huaren Pharmaceutical (300110.SZ): Its subsidiary has obtained a medical instruments registration certificate for disposable nasal oxygen tubes.
On July 18th, Gelonhui reported that Huaren Pharmaceutical (300110.SZ) announced that its wholly-owned subsidiary, Qingdao Huaren Medical Supplies Co., Ltd., recently received a registration certificate for medical instruments for the disposable nasal oxygen tube approved and issued by the Shandong Provincial Drug Administration.
Is It Smart To Buy Huaren Pharmaceutical Co., Ltd. (SZSE:300110) Before It Goes Ex-Dividend?
Huaren Pharmaceutical (300110.SZ) plans to distribute 0.21 yuan per 10 shares on July 10th ex-dividend.
Huaren Pharmaceutical (300110.SZ) announced that the annual equity distribution plan for the year 2023 is as follows: a cash dividend of RMB 1.00 (tax included) will be distributed to all shareholders for every 10 shares held.
Huaren Pharmaceutical (300110.SZ): terminates the previous change of the actual controller and again plans, where Xi'an State-owned Assets Supervision and Administration Commission may become the actual controller.
Huaren Pharmaceutical (300110.SZ) announced that its indirectly controlled shareholder, Xi'an Qujiang Cultural and Financial Holdings (Group) ...
Huaren Pharmaceutical (300110.SZ): Hemodialysis fluid (lactate-G1.5%) and Hemodialysis fluid (lactate-G2.5%) have undergone consistency evaluation and optimized production processes and quality standards.
On June 20th, Glonhui reported that Huaren Pharmaceutical (Stock Code: 300110.SZ) has recently received the "Drug Supplement Application Approval Letter" issued by the National Medical Products Administration for the peritoneal dialysis solution (lactate-G1.5%) and peritoneal dialysis solution (lactate-G2.5%). After examination, the product has passed the evaluation for the consistency of quality and efficacy of generic drugs. The following changes have been approved as well: 1. Changing the prescription and production process of the drug; 2. Changing the quality standard of the drug; 3. Revising the drug instructions; 4. Changing the packaging materials and containers that come into direct contact with the drug. Production process and quality standard.
No Data